MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) will participate in the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 4:00 pm (ET). CEO Michael Castagna will deliver a virtual presentation accessible via the company’s website. MannKind focuses on developing inhaled therapeutic products for endocrine and orphan lung diseases, notably commercializing Afrezza® (insulin human) Inhalation Powder, the only inhaled ultra-rapid-acting mealtime insulin in the U.S. The webcast will be available for 14 days post-event.

DANBURY, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a virtual presentation at the Oppenheimer 32^nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 4:00 pm (ET).

Interested parties can access a link to the webcast from the News & Events section of the Company’s website at Events & Presentations. The webcast replay will remain available for 14 days following the live presentation.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner, Biomm SA. MannKind was established in 1991, and is located in Danbury, Conn., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

Company Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com

FAQ

When is MannKind's presentation at the Oppenheimer Healthcare Conference?

MannKind's presentation is scheduled for March 15, 2022, at 4:00 pm (ET).

Who will represent MannKind at the Oppenheimer Conference?

CEO Michael Castagna will represent MannKind at the conference.

Where can I access MannKind's conference presentation?

You can access the presentation via the News & Events section on MannKind's website.

What is Afrezza and why is it significant for MannKind?

Afrezza is MannKind's inhaled ultra-rapid-acting mealtime insulin, the only product of its kind approved in the United States.

How long will the webcast of the MannKind presentation be available?

The webcast will remain available for 14 days after the live presentation.